Consensus on biomarkers for neuroendocrine tumour disease

Kjell Oberg, Irvin M. Modlin, Wouter De Herder, Marianne Pavel, David Klimstra, Andrea Frilling, David C. Metz, Anthony Heaney, Dik Kwekkeboom, Jonathan Strosberg, Timothy Meyer, Steven F. Moss, Kay Washington, Edward Wolin, Eric Liu, James Goldenring

Research output: Contribution to journalReview article

76 Citations (Scopus)

Abstract

Management of neuroendocrine neoplasia represents a clinical challenge because of its late presentation, lack of treatment options, and limitations in present imaging modalities and biomarkers to guide management. Monoanalyte biomarkers have poor sensitivity, specificity, and predictive ability. A National Cancer Institute summit, held in 2007, on neuroendocrine tumours noted biomarker limitations to be a crucial unmet need in the management of neuroendocrine tumours. A multinational consensus meeting of multidisciplinary experts in neuroendocrine tumours assessed the use of current biomarkers and defined the perquisites for novel biomarkers via the Delphi method. Consensus (at >75%) was achieved for 88 (82%) of 107 assessment questions. The panel concluded that circulating multianalyte biomarkers provide the highest sensitivity and specificity necessary for minimum disease detection and that this type of biomarker had sufficient information to predict treatment effectiveness and prognosis. The panel also concluded that no monoanalyte biomarker of neuroendocrine tumours has yet fulfilled these criteria and there is insufficient information to support the clinical use of miRNA or circulating tumour cells as useful prognostic markers for this disease. The panel considered that trials measuring multianalytes (eg, neuroendocrine gene transcripts) should also identify how such information can optimise the management of patients with neuroendocrine tumours.

Original languageEnglish (US)
Article number118
Pages (from-to)e435-e446
JournalThe Lancet Oncology
Volume16
Issue number9
DOIs
StatePublished - Sep 1 2015
Externally publishedYes

Fingerprint

Neuroendocrine Tumors
Biomarkers
Circulating Neoplastic Cells
Sensitivity and Specificity
National Cancer Institute (U.S.)
Tumor Biomarkers
MicroRNAs
Genes
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Oberg, K., Modlin, I. M., De Herder, W., Pavel, M., Klimstra, D., Frilling, A., ... Goldenring, J. (2015). Consensus on biomarkers for neuroendocrine tumour disease. The Lancet Oncology, 16(9), e435-e446. [118]. https://doi.org/10.1016/S1470-2045(15)00186-2

Consensus on biomarkers for neuroendocrine tumour disease. / Oberg, Kjell; Modlin, Irvin M.; De Herder, Wouter; Pavel, Marianne; Klimstra, David; Frilling, Andrea; Metz, David C.; Heaney, Anthony; Kwekkeboom, Dik; Strosberg, Jonathan; Meyer, Timothy; Moss, Steven F.; Washington, Kay; Wolin, Edward; Liu, Eric; Goldenring, James.

In: The Lancet Oncology, Vol. 16, No. 9, 118, 01.09.2015, p. e435-e446.

Research output: Contribution to journalReview article

Oberg, K, Modlin, IM, De Herder, W, Pavel, M, Klimstra, D, Frilling, A, Metz, DC, Heaney, A, Kwekkeboom, D, Strosberg, J, Meyer, T, Moss, SF, Washington, K, Wolin, E, Liu, E & Goldenring, J 2015, 'Consensus on biomarkers for neuroendocrine tumour disease', The Lancet Oncology, vol. 16, no. 9, 118, pp. e435-e446. https://doi.org/10.1016/S1470-2045(15)00186-2
Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A et al. Consensus on biomarkers for neuroendocrine tumour disease. The Lancet Oncology. 2015 Sep 1;16(9):e435-e446. 118. https://doi.org/10.1016/S1470-2045(15)00186-2
Oberg, Kjell ; Modlin, Irvin M. ; De Herder, Wouter ; Pavel, Marianne ; Klimstra, David ; Frilling, Andrea ; Metz, David C. ; Heaney, Anthony ; Kwekkeboom, Dik ; Strosberg, Jonathan ; Meyer, Timothy ; Moss, Steven F. ; Washington, Kay ; Wolin, Edward ; Liu, Eric ; Goldenring, James. / Consensus on biomarkers for neuroendocrine tumour disease. In: The Lancet Oncology. 2015 ; Vol. 16, No. 9. pp. e435-e446.
@article{958711d2001443688cd2aff46e9f2321,
title = "Consensus on biomarkers for neuroendocrine tumour disease",
abstract = "Management of neuroendocrine neoplasia represents a clinical challenge because of its late presentation, lack of treatment options, and limitations in present imaging modalities and biomarkers to guide management. Monoanalyte biomarkers have poor sensitivity, specificity, and predictive ability. A National Cancer Institute summit, held in 2007, on neuroendocrine tumours noted biomarker limitations to be a crucial unmet need in the management of neuroendocrine tumours. A multinational consensus meeting of multidisciplinary experts in neuroendocrine tumours assessed the use of current biomarkers and defined the perquisites for novel biomarkers via the Delphi method. Consensus (at >75{\%}) was achieved for 88 (82{\%}) of 107 assessment questions. The panel concluded that circulating multianalyte biomarkers provide the highest sensitivity and specificity necessary for minimum disease detection and that this type of biomarker had sufficient information to predict treatment effectiveness and prognosis. The panel also concluded that no monoanalyte biomarker of neuroendocrine tumours has yet fulfilled these criteria and there is insufficient information to support the clinical use of miRNA or circulating tumour cells as useful prognostic markers for this disease. The panel considered that trials measuring multianalytes (eg, neuroendocrine gene transcripts) should also identify how such information can optimise the management of patients with neuroendocrine tumours.",
author = "Kjell Oberg and Modlin, {Irvin M.} and {De Herder}, Wouter and Marianne Pavel and David Klimstra and Andrea Frilling and Metz, {David C.} and Anthony Heaney and Dik Kwekkeboom and Jonathan Strosberg and Timothy Meyer and Moss, {Steven F.} and Kay Washington and Edward Wolin and Eric Liu and James Goldenring",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/S1470-2045(15)00186-2",
language = "English (US)",
volume = "16",
pages = "e435--e446",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "9",

}

TY - JOUR

T1 - Consensus on biomarkers for neuroendocrine tumour disease

AU - Oberg, Kjell

AU - Modlin, Irvin M.

AU - De Herder, Wouter

AU - Pavel, Marianne

AU - Klimstra, David

AU - Frilling, Andrea

AU - Metz, David C.

AU - Heaney, Anthony

AU - Kwekkeboom, Dik

AU - Strosberg, Jonathan

AU - Meyer, Timothy

AU - Moss, Steven F.

AU - Washington, Kay

AU - Wolin, Edward

AU - Liu, Eric

AU - Goldenring, James

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Management of neuroendocrine neoplasia represents a clinical challenge because of its late presentation, lack of treatment options, and limitations in present imaging modalities and biomarkers to guide management. Monoanalyte biomarkers have poor sensitivity, specificity, and predictive ability. A National Cancer Institute summit, held in 2007, on neuroendocrine tumours noted biomarker limitations to be a crucial unmet need in the management of neuroendocrine tumours. A multinational consensus meeting of multidisciplinary experts in neuroendocrine tumours assessed the use of current biomarkers and defined the perquisites for novel biomarkers via the Delphi method. Consensus (at >75%) was achieved for 88 (82%) of 107 assessment questions. The panel concluded that circulating multianalyte biomarkers provide the highest sensitivity and specificity necessary for minimum disease detection and that this type of biomarker had sufficient information to predict treatment effectiveness and prognosis. The panel also concluded that no monoanalyte biomarker of neuroendocrine tumours has yet fulfilled these criteria and there is insufficient information to support the clinical use of miRNA or circulating tumour cells as useful prognostic markers for this disease. The panel considered that trials measuring multianalytes (eg, neuroendocrine gene transcripts) should also identify how such information can optimise the management of patients with neuroendocrine tumours.

AB - Management of neuroendocrine neoplasia represents a clinical challenge because of its late presentation, lack of treatment options, and limitations in present imaging modalities and biomarkers to guide management. Monoanalyte biomarkers have poor sensitivity, specificity, and predictive ability. A National Cancer Institute summit, held in 2007, on neuroendocrine tumours noted biomarker limitations to be a crucial unmet need in the management of neuroendocrine tumours. A multinational consensus meeting of multidisciplinary experts in neuroendocrine tumours assessed the use of current biomarkers and defined the perquisites for novel biomarkers via the Delphi method. Consensus (at >75%) was achieved for 88 (82%) of 107 assessment questions. The panel concluded that circulating multianalyte biomarkers provide the highest sensitivity and specificity necessary for minimum disease detection and that this type of biomarker had sufficient information to predict treatment effectiveness and prognosis. The panel also concluded that no monoanalyte biomarker of neuroendocrine tumours has yet fulfilled these criteria and there is insufficient information to support the clinical use of miRNA or circulating tumour cells as useful prognostic markers for this disease. The panel considered that trials measuring multianalytes (eg, neuroendocrine gene transcripts) should also identify how such information can optimise the management of patients with neuroendocrine tumours.

UR - http://www.scopus.com/inward/record.url?scp=84940532180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940532180&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(15)00186-2

DO - 10.1016/S1470-2045(15)00186-2

M3 - Review article

C2 - 26370353

AN - SCOPUS:84940532180

VL - 16

SP - e435-e446

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 9

M1 - 118

ER -